 Scopus BioPharma Inc. NASDAQ: SCPS said the U.S. Food and Drug Administration FDA approved its IND investigational new drug application on Monday for CpG-STAT3siRNA its distinctive immuno-oncology RNA therapy that targets multiple types of cancers. Impact on the share price Following the announcement, Scopus BioPharma jumped roughly 200 in the stock market on Monday ... The post Heres why Scopus BioPharma gained 200 on Monday appeared first on Invezz. 